RT Journal Article
SR Electronic
T1 SARS-CoV-2 seropositivity and seroconversion in patients undergoing active cancer-directed therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.15.21249810
DO 10.1101/2021.01.15.21249810
A1 Sun, Lova
A1 Surya, Sanjna
A1 Goodman, Noah G.
A1 Le, Anh N.
A1 Kelly, Gregory
A1 Owoyemi, Olutosin
A1 Desai, Heena
A1 Zheng, Cathy
A1 DeLuca, Shannon
A1 Good, Madeline L.
A1 Hussain, Jasmin
A1 Jeffries, Seth D.
A1 Kry, Yolanda R.
A1 Kugler, Emily M.
A1 Mansour, Maikel
A1 Ndicu, John
A1 Osei-Akoto, AnnaClaire
A1 Prior, Timothy
A1 Pundock, Stacy L.
A1 Varughese, Lisa A.
A1 Weaver, JoEllen
A1 Doucette, Abigail
A1 Dudek, Scott
A1 Verma, Shefali Setia
A1 Gouma, Sigrid
A1 Weirick, Madison E.
A1 McAllister, Christopher M.
A1 Bange, Erin
A1 Gabriel, Peter
A1 Ritchie, Marylyn
A1 Rader, Daniel J.
A1 Vonderheide, Robert H.
A1 Schuchter, Lynn M
A1 Verma, Anurag
A1 Maillard, Ivan
A1 Mamtani, Ronac
A1 Hensley, Scott E.
A1 Gross, Robert
A1 Wileyto, E. Paul
A1 Huang, Alexander C.
A1 Maxwell, Kara N.
A1 DeMichele, Angela
YR 2021
UL http://medrxiv.org/content/early/2021/01/16/2021.01.15.21249810.abstract
AB Multiple studies have demonstrated the negative impact of cancer care delays during the COVID-19 pandemic, and transmission mitigation techniques are imperative for continued cancer care delivery. To gauge the effectiveness of these measures at the University of Pennsylvania, we conducted a longitudinal study of SARS-CoV-2 antibody seropositivity and seroconversion in patients presenting to infusion centers for cancer-directed therapy between 5/21/2020 and 10/8/2020. Participants completed questionnaires and had up to five serial blood collections. Of 124 enrolled patients, only two (1.6%) had detectable SARS-CoV-2 antibodies on initial blood draw, and no initially seronegative patients developed newly detectable antibodies on subsequent blood draw(s), corresponding to a seroconversion rate of 0% (95%CI 0.0-4.1%) over 14.8 person-years of follow up, with a median of 13 healthcare visits per patient. These results suggest that cancer patients receiving in-person care at a facility with aggressive mitigation efforts have an extremely low likelihood of COVID-19 infection.Competing Interest StatementRHV reports having received consulting fees or honoraria from Medimmune and Verastem; and research funding from Fibrogen, Janssen, and Lilly. He is a member of the Lustgarten Therapeutics Advisory working group. He is an inventor on a licensed patents relating to cancer cellular immunotherapy and cancer vaccines, and receives royalties from Childrens Hospital Boston for a licensed research-only monoclonal antibody. SEH has received consultancy fee from Sanofi Pasteur, Lumen, Novavax, and Merck for work unrelated to this report. Other authors declare that they have no competing interests.Funding StatementThis work was supported by the National Institutes of Health (P30-CA016520 to Abramson Cancer Center and RHV), a gift from the Smilow family, the National Center for Advancing Translational Sciences of the National Institutes of Health under CT6SA Award Number UL1TR001878, the Tara Miller Melanoma Excellence Fund, and the Perelman School of Medicine at the University of Pennsylvania. J. Lurie, J. Embiid, J. Harris, and D. Blitzer provided philanthropic support that was critical for establishing the serological assays used in this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review board at Penn Medicine under IRB protocol #813913.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on request. The data underlying this article will be shared on reasonable request to the corresponding author.